Further examination of DNA damage in CP-resistant cells are needed to test the hypotheses mentioned above, but it is clear that targeting RAP1 directs the future approach against the resistant subset of NSCLC cells after CP treatment. Here, TERF2IP is linked to non-small cell lung carcinoma.